Form 4: Alumis CSO Granted Stock Options

Alumis Inc.'s Chief Scientific Officer, David M. Goldstein, was granted 216,675 stock options with an exercise price of $26.31, vesting over four years.

Summary

• David M. Goldstein, Chief Scientific Officer of Alumis Inc., was granted 216,675 stock options.
• The options have an exercise price of $26.31 per share.
• The grant date for these options was January 26, 2026.
• The options expire on January 25, 2036.
• Vesting schedule: 25% of the shares vest on January 26, 2027, with the remaining shares vesting in equal monthly installments over the subsequent 36 months, contingent on continuous service.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal for retention and alignment of interests, though it introduces potential future dilution. It's a standard practice, so not overwhelmingly positive or negative, but leans positive for stability.

Positives

• The grant of stock options to the Chief Scientific Officer aligns management's incentives with shareholder interests, encouraging long-term commitment and performance.
• The significant number of options (216,675) indicates a substantial incentive for the CSO to contribute to the company's growth and success.

Negatives

• The exercise price of $26.31 per share means the stock price must rise above this level for the options to have intrinsic value, representing a potential dilution risk if exercised in the future.

Risks

• Dilution Risk: The future exercise of these options could lead to an increase in the number of outstanding shares, potentially diluting the value of existing shareholders' holdings.
• Performance Risk: The value of the options is contingent on the company's stock price performance, which is subject to market conditions and the company's operational success.
• Retention Risk: The vesting schedule ties the options to continuous service, meaning the company risks losing the CSO's expertise if service is not maintained.

Future Outlook

The vesting schedule extending over four years (until January 2027 for the first tranche, and then 36 months thereafter) indicates a long-term incentive structure designed to retain the Chief Scientific Officer and align their interests with the company's sustained growth and future performance.

Industry Context

The grant of stock options is a standard practice in the biotechnology and pharmaceutical industries (where Alumis Inc. likely operates, given "Chief Scientific Officer") to attract, retain, and incentivize key scientific and executive talent. Such grants are crucial for companies with long development cycles and high R&D costs, where long-term commitment is essential.

Comparison to Industry Standards

• The use of stock options as a long-term incentive for a Chief Scientific Officer is a common compensation practice across the biotech and pharmaceutical sectors, comparable to companies like Moderna, BioNTech, or Regeneron, which heavily rely on scientific leadership.
• The vesting schedule, with a one-year cliff followed by monthly vesting over three years, is a typical structure designed to ensure executive retention and align incentives with multi-year strategic goals, similar to those observed in many high-growth technology and life sciences companies.
• The exercise price of $26.31, while specific to Alumis, would be evaluated against the company's stock performance and peer group valuations to assess its potential for future value creation for the option holder.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also benefit from incentivized management performance.
• Employees: May signal stability in leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• The Chief Scientific Officer will continue to serve the company to meet the vesting conditions of the stock options.
• The company's stock performance will determine the future value and potential exercise of these options.

Key Dates

Recommendation

This Form 4 filing reports a routine stock option grant to a key executive, which is a standard compensation practice. It does not contain information that would fundamentally alter the investment thesis for Alumis Inc. While it aligns management incentives, it doesn't provide new operational or financial data to warrant a change from a 'hold' position based solely on this filing. Investors should continue to monitor the company's core business performance and broader market trends.

Keywords

Alumis Inc., ALMS, Stock Options, Form 4, Insider Transaction, Equity Incentive, Chief Scientific Officer, David M. Goldstein, Vesting